IPF cases projected to rise steadily in major markets through 2034

Diagnosed cases of idiopathic pulmonary fibrosis (IPF) in the seven major markets are expected to climb from just under 200,000 in 2024 to more than 230,000 in 2034, according to new GlobalData analysis. The firm estimates a 1.58% annual growth rate over the period.

The USA is forecast to account for the largest share, with nearly 135,000 cases by 2034, while the UK will see the fewest at around 11,700. GlobalData highlighted that more than three-quarters of cases occur in adults aged 60 years and older, with men affected more often than women.

IPF is a progressive interstitial lung disease that scars the tissue around the lungs’ air sacs, making breathing increasingly difficult. Environmental factors such as smoking and respiratory infections, along with age-related changes, are among the suspected triggers. The condition has a poor prognosis, with median survival of three to five years.